Login
$PFE
$28.89 +$0.03 (0.1%) After hours

$PFE 8-K SEC Filings

Filed On Filing
03 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experience

03 Nov 2026 8-K: Results of Operations and Financial Condition

■Focused Execution Drove 32% Operational Revenue Growth of Launched and Acquired Products(1)

04 Aug 2026 8-K: Results of Operations and Financial Condition

■Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1)

18 Jun 2026 8-K: Regulation FD Disclosure

Following the disclosure of Pfizer’s Chief Financial Officer transition announcement on June 18, 2026, Pfizer today is reaffirming its fiscal year 2026 guidance introduced December 16, 2025 and reaffirmed on its first quarter earnings ca...

18 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

NEW YORK, June 18, 2026—Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutic...

05 May 2026 8-K: Results of Operations and Financial Condition

■Earnings Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products(1)

27 Apr 2026 8-K: Submission of Matters to a Vote of Security Holders
03 Feb 2026 8-K: Results of Operations and Financial Condition

■Focused Execution Drives Strong Full-Year 2025 EPS Performance

16 Dec 2025 8-K: Regulation FD Disclosure

NEW YORK, December 16, 2025 — Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and reaffirming all other components of full-year 2025 financial gu...

21 Nov 2025 8-K: Other Events

SIXTH SUPPLEMENTAL INDENTURE, dated as of November 21, 2025 (the “Sixth Supplemental Indenture”), between Pfizer Inc., a Delaware corporation (the “Company”), and The Bank of New York Mellon, a New York banking corporation, as trustee (t...

13 Nov 2025 8-K: Other Events

On November 13, 2025, Pfizer Inc. (“Pfizer” or the “Company”) completed the previously announced acquisition of Metsera, Inc., a Delaware corporation (“Metsera”), pursuant to the Agreement and Plan of Merger, dated as of September 21, 20...

04 Nov 2025 8-K: Results of Operations and Financial Condition

■Landmark Agreement Reached with U.S. Government Provides Longer-Term Business Clarity

05 Aug 2025 8-K: Results of Operations and Financial Condition

■Expanded Programs On Track to Deliver Net Cost Savings Targets

19 May 2025 8-K: Other Events

This reconciliation and tie shall not, for any purpose, be deemed to be a part of the Indenture.

29 Apr 2025 8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities

■Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment

28 Apr 2025 8-K: Submission of Matters to a Vote of Security Holders
04 Feb 2025 8-K: Results of Operations and Financial Condition

–Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 12% Operationally

17 Dec 2024 8-K: Regulation FD Disclosure

NEW YORK, December 17, 2024 — Pfizer Inc. (NYSE:PFE) today provided its full-year 2025 guidance(1) and reaffirmed its October 29, 2024 full-year 2024 guidance(1). The accompanying presentation can be found at www.pfizer.com/investors.

29 Oct 2024 8-K: Results of Operations and Financial Condition

–Excluding Contributions from Paxlovid and Comirnaty(3), Revenues Grew 14% Operationally

15 Oct 2024 8-K: Departure/Election of Directors or Officers; Compensation

NEW YORK, October 15, 2024 – Pfizer Inc. (NYSE: PFE) today announced the election of Mortimer (“Tim”) J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Mr. B...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support